Researchers have found that the gene mesothelin can be targeted by new antibody-drug conjugates to treat acute myeloid leukaemia in children.
List view / Grid view
ImmunoGen’s IMGN529 demonstrates synergistic activity with rituximab in preclinical models of non-hodgkin lymphoma
18 June 2015 | By Victoria White
Findings from ImmunoGen’s preclinical assessments of IMGN529 in combination with rituximab have been presented at ICML 2015...